- Home
- FTI vs GMAB Comparison
FTI vs GMAB Comparison
Compare FTI & GMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FTI
- GMAB
- Stock Information
- Founded
- FTI 1884
- GMAB 1999
- Country
- FTI United States
- GMAB Denmark
- Employees
- FTI N/A
- GMAB N/A
- Industry
- FTI Metal Fabrications
- GMAB Biotechnology: Pharmaceutical Preparations
- Sector
- FTI Industrials
- GMAB Health Care
- Exchange
- FTI Nasdaq
- GMAB Nasdaq
- Market Cap
- FTI 16.4B
- GMAB 17.4B
- IPO Year
- FTI N/A
- GMAB N/A
- Fundamental
- Price
- FTI $40.71
- GMAB $29.05
- Analyst Decision
- FTI Strong Buy
- GMAB Strong Buy
- Analyst Count
- FTI 12
- GMAB 7
- Target Price
- FTI $42.40
- GMAB $41.17
- AVG Volume (30 Days)
- FTI 4.6M
- GMAB 3.0M
- Earning Date
- FTI 10-23-2025
- GMAB 11-06-2025
- Dividend Yield
- FTI 0.49%
- GMAB N/A
- EPS Growth
- FTI 59.09
- GMAB 77.72
- EPS
- FTI 2.28
- GMAB 21.62
- Revenue
- FTI $9,803,000,000.00
- GMAB $3,646,881,232.00
- Revenue This Year
- FTI $9.91
- GMAB $24.25
- Revenue Next Year
- FTI $7.50
- GMAB $16.29
- P/E Ratio
- FTI $17.77
- GMAB $13.08
- Revenue Growth
- FTI 11.44
- GMAB 32.97
- 52 Week Low
- FTI $22.12
- GMAB $17.24
- 52 Week High
- FTI $41.35
- GMAB $33.65
- Technical
- Relative Strength Index (RSI)
- FTI 63.19
- GMAB 40.72
- Support Level
- FTI $35.29
- GMAB $28.94
- Resistance Level
- FTI $41.18
- GMAB $30.24
- Average True Range (ATR)
- FTI 1.23
- GMAB 0.67
- MACD
- FTI 0.50
- GMAB -0.63
- Stochastic Oscillator
- FTI 89.51
- GMAB 2.34
About FTI TechnipFMC plc
TechnipFMC is the largest provider of offshore oilfield services, offering integrated deep-water offshore oil and gas development solutions that span the full spectrum of subsea equipment and subsea construction services. The company also provides various pieces of surface equipment used with onshore oil and gas wells. TechnipFMC originated with the 2017 merger of Technip and FMC Technologies.
About GMAB Genmab A/S ADS
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.